PortalPublikationenNew antiangiogenic strategies beyond inhibition of vascular ...

New antiangiogenic strategies beyond inhibition of vascular endothelial growth factor with special focus on axon guidance molecules

Standard

New antiangiogenic strategies beyond inhibition of vascular endothelial growth factor with special focus on axon guidance molecules. / Pircher, Andreas; Wellbrock, Jasmin; Fiedler, Walter; Heidegger, Isabel; Gunsilius, Eberhard; Hilbe, Wolfgang.

in: NEURO-ONCOLOGY, Jahrgang 86, Nr. 1, 01.01.2014, S. 46-52.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Pircher, A, Wellbrock, J, Fiedler, W, Heidegger, I, Gunsilius, E & Hilbe, W 2014, 'New antiangiogenic strategies beyond inhibition of vascular endothelial growth factor with special focus on axon guidance molecules', NEURO-ONCOLOGY, Jg. 86, Nr. 1, S. 46-52. https://doi.org/10.1159/000356871

APA

Pircher, A., Wellbrock, J., Fiedler, W., Heidegger, I., Gunsilius, E., & Hilbe, W. (2014). New antiangiogenic strategies beyond inhibition of vascular endothelial growth factor with special focus on axon guidance molecules. NEURO-ONCOLOGY, 86(1), 46-52. https://doi.org/10.1159/000356871

Vancouver

Pircher A, Wellbrock J, Fiedler W, Heidegger I, Gunsilius E, Hilbe W. New antiangiogenic strategies beyond inhibition of vascular endothelial growth factor with special focus on axon guidance molecules. NEURO-ONCOLOGY. 2014 Jan 1;86(1):46-52. https://doi.org/10.1159/000356871

Bibtex

@article{23a351f00a98489c891416ad1099b719,
title = "New antiangiogenic strategies beyond inhibition of vascular endothelial growth factor with special focus on axon guidance molecules",
abstract = "Since the approval of the first antiangiogenic agent bevacizumab, a neutralizing antibody against the vascular endothelial growth factor (VEGF), antiangiogenic therapies augmented the standard armamentarium of anticancer therapies and proved their clinical efficacy. Nevertheless, antiangiogenic strategies could not fulfill the expected hopes. In clinical routine, therapy responses to antiangiogenic therapies were mostly transient and most of the patients developed evasive resistance mechanisms during therapy. Further, no predictive biomarker for therapy response could be developed, hampering the clinical development of these agents and triggering skepticism. In the past years, knowledge on the biology of angiogenesis increased and the role of tumor hypoxia was better characterized and identified as the driver for angiogenic regulation mechanisms. Besides VEGF, new angiogenic and antiangiogenic factors were characterized and the process of endothelial cell migration, proliferation and vessel formation was better elucidated. Thus, a strong connection to neural development and axon guidance molecules like netrins, Slit proteins, semaphorins, ephrins and their cognate receptors UNC5, Robo1-4, neuropilin and EphB was identified. The aim of this review is to present the importance of these axon guidance molecules with special focus on Robo4 and semaphorins in tumor angiogenesis and to highlight their value as potential targets for new antiangiogenic therapies.",
keywords = "Angiogenesis Inhibitors, Animals, Axons, Humans, Intercellular Signaling Peptides and Proteins, Neoplasms, Nerve Growth Factors, Nerve Tissue Proteins, Receptors, Cell Surface, Semaphorins, Signal Transduction, Tumor Suppressor Proteins, Vascular Endothelial Growth Factor A",
author = "Andreas Pircher and Jasmin Wellbrock and Walter Fiedler and Isabel Heidegger and Eberhard Gunsilius and Wolfgang Hilbe",
note = "{\textcopyright} 2014 S. Karger AG, Basel.",
year = "2014",
month = jan,
day = "1",
doi = "10.1159/000356871",
language = "English",
volume = "86",
pages = "46--52",
journal = "NEURO-ONCOLOGY",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "1",

}

RIS

TY - JOUR

T1 - New antiangiogenic strategies beyond inhibition of vascular endothelial growth factor with special focus on axon guidance molecules

AU - Pircher, Andreas

AU - Wellbrock, Jasmin

AU - Fiedler, Walter

AU - Heidegger, Isabel

AU - Gunsilius, Eberhard

AU - Hilbe, Wolfgang

N1 - © 2014 S. Karger AG, Basel.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Since the approval of the first antiangiogenic agent bevacizumab, a neutralizing antibody against the vascular endothelial growth factor (VEGF), antiangiogenic therapies augmented the standard armamentarium of anticancer therapies and proved their clinical efficacy. Nevertheless, antiangiogenic strategies could not fulfill the expected hopes. In clinical routine, therapy responses to antiangiogenic therapies were mostly transient and most of the patients developed evasive resistance mechanisms during therapy. Further, no predictive biomarker for therapy response could be developed, hampering the clinical development of these agents and triggering skepticism. In the past years, knowledge on the biology of angiogenesis increased and the role of tumor hypoxia was better characterized and identified as the driver for angiogenic regulation mechanisms. Besides VEGF, new angiogenic and antiangiogenic factors were characterized and the process of endothelial cell migration, proliferation and vessel formation was better elucidated. Thus, a strong connection to neural development and axon guidance molecules like netrins, Slit proteins, semaphorins, ephrins and their cognate receptors UNC5, Robo1-4, neuropilin and EphB was identified. The aim of this review is to present the importance of these axon guidance molecules with special focus on Robo4 and semaphorins in tumor angiogenesis and to highlight their value as potential targets for new antiangiogenic therapies.

AB - Since the approval of the first antiangiogenic agent bevacizumab, a neutralizing antibody against the vascular endothelial growth factor (VEGF), antiangiogenic therapies augmented the standard armamentarium of anticancer therapies and proved their clinical efficacy. Nevertheless, antiangiogenic strategies could not fulfill the expected hopes. In clinical routine, therapy responses to antiangiogenic therapies were mostly transient and most of the patients developed evasive resistance mechanisms during therapy. Further, no predictive biomarker for therapy response could be developed, hampering the clinical development of these agents and triggering skepticism. In the past years, knowledge on the biology of angiogenesis increased and the role of tumor hypoxia was better characterized and identified as the driver for angiogenic regulation mechanisms. Besides VEGF, new angiogenic and antiangiogenic factors were characterized and the process of endothelial cell migration, proliferation and vessel formation was better elucidated. Thus, a strong connection to neural development and axon guidance molecules like netrins, Slit proteins, semaphorins, ephrins and their cognate receptors UNC5, Robo1-4, neuropilin and EphB was identified. The aim of this review is to present the importance of these axon guidance molecules with special focus on Robo4 and semaphorins in tumor angiogenesis and to highlight their value as potential targets for new antiangiogenic therapies.

KW - Angiogenesis Inhibitors

KW - Animals

KW - Axons

KW - Humans

KW - Intercellular Signaling Peptides and Proteins

KW - Neoplasms

KW - Nerve Growth Factors

KW - Nerve Tissue Proteins

KW - Receptors, Cell Surface

KW - Semaphorins

KW - Signal Transduction

KW - Tumor Suppressor Proteins

KW - Vascular Endothelial Growth Factor A

U2 - 10.1159/000356871

DO - 10.1159/000356871

M3 - SCORING: Journal article

C2 - 24401553

VL - 86

SP - 46

EP - 52

JO - NEURO-ONCOLOGY

JF - NEURO-ONCOLOGY

SN - 1522-8517

IS - 1

ER -